Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innate Pharma acquires full rights to anti-NKG2A antibody from Novo Nordisk
For the acquisition, Innate Pharma will pay €2m in cash and 600,000 shares to Novo Nordisk for licencing the anti-NKG2A antibody. In addition, Novo Nordisk may be eligible
For the acquisition, Innate Pharma will pay €2m in cash and 600,000 shares to Novo Nordisk for licencing the anti-NKG2A antibody. In addition, Novo Nordisk may be eligible
A Phase I/II clinical trial will be carried out by Pfizer and Merck that will assess the safety and anti-cancer efficacy of MK-3475 combined with Pfizer’s small molecule
The company previously had exclusive global distribution rights and served as the distributor for DUROLANE in Europe, Canada and Australia. Under the new deal, Galderma will continue to
In May 2011, BioAlliance signed a licensing deal with Sosei to carry out bridging development program and commercialization rights in Japan for Loramyc in the treatment of oropharyngeal
The trial is designed to assess Oxycodone DETERx versus placebo in opioid-experienced and opioid-naïve subjects with moderate-to-severe chronic low back pain. According to company, patients who achieve a
The spray is used to provide 24 hour relief of the full range of seasonal and year-round nasal allergy symptoms, including nasal congestion, in adults and children two
Since 2009, the two partners have been working together on the development of novel treatment options for cancer patients. Over the next five years, Bayer and DKFZ will
The new Tramore laboratory, which is key to the growth of the company’s DNA sequencing service in Ireland, is positioned between Cork and Dublin, providing an opportunity to
The new deal is focused on the discovery and development of several predefined Nanobody candidates (including bi- and tri-specifics) directed toward ‘immune checkpoint modulators’. Immune checkpoint modulators are
The acquisition gives AstraZeneca ownership of the intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, including Onglyza, Kombiglyze XR, Komboglyze, dapagliflozin,